Can a patient taking sacubitril/valsartan (Entresto) 50 mg who develops hypotension from his other antihypertensive medications safely stop or reduce the dose?

Can Entresto Be Safely Reduced or Stopped Due to Hypotension?

Do not stop Entresto—instead, first reduce or discontinue other blood pressure medications (especially diuretics if not congested), and only if hypotension persists despite these measures should you temporarily reduce the Entresto dose, with permanent discontinuation rarely required. 1

Prioritize Keeping Entresto: The Evidence

The FDA label explicitly states that "permanent discontinuation of therapy is usually not required" for hypotension 1. This is critical because Entresto reduces mortality and morbidity in heart failure patients, making it foundational therapy that should be preserved whenever possible 2.

Step-by-Step Management Algorithm

1. First: Address Other Causes of Hypotension

• Reduce diuretics if your relative shows no signs of congestion (no leg swelling, shortness of breath, weight gain) 3
• Adjust other antihypertensive medications before touching Entresto 1
• Correct volume depletion if present (dehydration, excessive diuretic use) 1

2. If Hypotension Persists: Modify Entresto Temporarily

• Reduce the dose rather than stopping completely 1
• At 50 mg twice daily, he's already on a low dose—could temporarily hold doses and restart at 24/26 mg twice daily
• Monitor closely during adjustment period

3. Key Safety Context

The 2025 European Heart Failure guidelines emphasize that SGLT2 inhibitors and MRAs rarely cause hypotension, while Entresto is more likely to do so 3. This means:

• If he's on other heart failure medications, those should generally be continued
• Focus blood pressure management on diuretics and non-essential antihypertensives first

Critical Evidence on Hypotension with Entresto

Hypotension is common but manageable: In PARADIGM-HF, 11.1% experienced symptomatic hypotension, yet the mortality benefit of Entresto was maintained regardless of hypotension occurrence 3. Importantly, patients with baseline systolic BP 95-110 mmHg actually experienced mild BP increases over time on Entresto 3.

Real-world data confirms tolerability: Japanese post-marketing surveillance showed hypotension-related adverse events in only 7.8 per 100 patient-years, with most patients successfully continuing therapy 4.

Common Pitfalls to Avoid

1. Don't stop Entresto first—it provides survival benefit that other BP medications don't 2
2. Don't assume all hypotension is dangerous—asymptomatic low BP (even <100 mmHg systolic) doesn't require intervention if perfusion is adequate 3
3. Don't reduce Entresto if he's congested—address volume overload with diuretics instead 3

When Symptoms Matter Most

Symptomatic hypotension (dizziness, lightheadedness, near-syncope) requires action, but asymptomatic low blood pressure readings alone do not mandate dose changes 3. The 2025 HFA consensus specifically notes that BP values must be interpreted within clinical context 3.

Monitoring During Adjustment

If dose reduction becomes necessary:

• Check BP sitting and standing (orthostatic changes matter)
• Monitor for signs of worsening heart failure (weight gain, increased shortness of breath)
• Reassess kidney function and potassium within 1-2 weeks 1
• Attempt up-titration again once BP stabilizes 1

The goal is to maintain Entresto at the highest tolerated dose while managing hypotension through adjustment of other medications first.